Ask about coverage for semaglutide injection for weight management
Wegovy is approved for weight loss (2.4 mg)
Gastrointestinal tolerability of onceweekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Last reviewed: June 30, 2026 Last updated: June 30, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Compounded semaglutide , brand-name injections, and oral formulations all carry the same indirect risk profile related to gastrointestinal side effects and dehydration
By mimicking the effect of insulin to lower your blood sugar levels it